Synaptic inhibitory dynamics drive benzodiazepine response in pediatric status epilepticus
Related Experiment Video
Updated: May 13, 2025
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Tommaso Fedele1,2, Richard J Burman1,3, Anne Steinberg1
1Department of Pediatric Neurology, University Children's Hospital Zurich and University of Zurich, Zurich, Switzerland.
Insights
Pediatric status epilepticus (SE) treatment with benzodiazepines (BZPs) can fail due to altered synaptic inhibition. Computational modeling of EEG data reveals these changes, offering insights into treatment resistance in children.
Area of Science:
- Neuroscience
- Computational Biology
- Pediatric Neurology
Background:
- Pediatric status epilepticus (SE) is a critical neurological emergency.
- Benzodiazepines (BZPs) are first-line SE treatment but are ineffective in over a third of pediatric cases.
- Animal models suggest SE-induced changes in synaptic inhibition may reduce BZP efficacy, but this is unconfirmed in children.
Purpose of the Study:
- To investigate the role of synaptic inhibition alterations in BZP treatment response in pediatric SE.
- To explore the relevance of animal model findings to clinical pediatric SE.
- To demonstrate the utility of computational modeling in understanding neurological disorders.
Main Methods:
- Utilized clinical electroencephalographic (EEG) recordings from pediatric SE patients.
- Applied dynamic causal modeling (DCM) to infer cortical synaptic coupling parameters.
- Analyzed EEG data across different oscillatory states to link synaptic changes to BZP responsiveness.
Main Results:
- Dynamic alterations in inhibitory synaptic coupling correlated with BZP treatment responsiveness in pediatric SE.
- These synaptic changes influenced the transition from ictal to interictal states observed in EEG.
- In silico simulations showed alternative seizure termination pathways in models resistant to BZPs.
Conclusions:
- Findings confirm that changes in synaptic inhibition are a key factor in BZP response during pediatric SE.
- The study validates the use of computational modeling to bridge basic science discoveries with clinical observations in neurological disorders.
- This approach enhances understanding of abnormal brain states in conditions like SE.
Objective:
Pediatric status epilepticus (SE) is a medical emergency associated with significant morbidity. Benzodiazepines (BZPs) are the current first-line treatment, but do not work in more than one third of children presenting with SE. Animal studies have shown that SE can cause changes in synaptic inhibition signaling that can ultimately lead to BZPs becoming ineffective. However, the relevance of these mechanisms in pediatric patients with SE remains unknown.
Methods:
To test this hypothesis, we combine clinical electroencephalographic (EEG) recordings with dynamic causal modeling (DCM). This approach allows model-based inference of cortical synaptic coupling parameters based on EEG recorded across distinct oscillatory states.
Results:
Our DCM revealed that dynamic changes in inhibitory synaptic coupling explain differences in EEG power spectra associated with BZP treatment responsiveness and guide the transition from ictal to interictal state. Furthermore, in silico simulations demonstrate that there are alternative routes to seizure termination even in cortical circuit models unresponsive to BZPs.
Significance:
Together, our findings confirm that alterations in synaptic inhibition underlie BZP response during pediatric SE. More broadly, this work further demonstrates the utility of computational modeling to validate insights from basic science in clinically accessible recordings in neurological disorders characterized by abnormal brain states.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:28Integration of Synaptic Events
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14CNS Depressants: Barbiturates and Benzodiazepines